{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:34:07Z","timestamp":1790436847478,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01154-z","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:01:37Z","timestamp":1728903697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO\u2019s pharmacovigilance database"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-2701","authenticated-orcid":false,"given":"Pierre-Marie","family":"Morice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Khalife-Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Sassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Lelong-Boulouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Danu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9640","authenticated-orcid":false,"given":"Aline","family":"Renneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0449-6261","authenticated-orcid":false,"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-294X","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Micol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102099","volume":"62","author":"JR Jones","year":"2023","unstructured":"Jones JR, Cairns DA, Menzies T, Pawlyn C, Davies FE, Sigsworth R, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine. 2023;62:102099.","journal-title":"EClinicalMedicine"},{"key":"1154_CR2","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, Jung S-H, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431\u201342.","journal-title":"Lancet Haematol"},{"key":"1154_CR3","doi-asserted-by":"publisher","first-page":"i157","DOI":"10.1136\/bmj.i157","volume":"352","author":"L Zorzela","year":"2016","unstructured":"Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157.","journal-title":"BMJ"},{"key":"1154_CR4","doi-asserted-by":"crossref","unstructured":"Morton S, Murad M, O\u2019Connor E, Lee C, Booth M, Vandermeer B et al. Quantitative Synthesis\u2014An Update - Methods Guide for Effectiveness and Comparative Effectiveness Reviews - NCBI Bookshelf. 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519365\/ (accessed 18 Mar2020).","DOI":"10.23970\/AHRQEPCMETHGUIDE3"},{"key":"1154_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jclinepi.2017.04.023","volume":"86","author":"J-L Faillie","year":"2017","unstructured":"Faillie J-L, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, et al. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol. 2017;86:168\u201375.","journal-title":"J Clin Epidemiol"},{"key":"1154_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101070","volume":"60","author":"YJRA Riazat-Kesh","year":"2023","unstructured":"Riazat-Kesh YJRA, Mascarenhas J, Bar-Natan M. \u2018Secondary\u2019 acute lymphoblastic\/lymphocytic leukemia - done playing second fiddle? Blood Rev. 2023;60:101070.","journal-title":"Blood Rev"},{"key":"1154_CR7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1154_CR8","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","volume":"28","author":"V Marmouset","year":"2022","unstructured":"Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, et al. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. Clin Cancer Res J Am Assoc Cancer Res. 2022;28:5211\u201320.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1154_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.bulcan.2023.02.022","volume":"110","author":"A Renneville","year":"2023","unstructured":"Renneville A, Bernard E, Micol J-B. Therapy-related myelodysplastic syndromes in the genomics era. Bull Cancer (Paris). 2023;110:1129\u201340.","journal-title":"Bull Cancer (Paris)"},{"key":"1154_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/2643-3230.BCD-23-0106","volume":"5","author":"C Saygin","year":"2024","unstructured":"Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, et al. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal Hematopoiesis. Blood Cancer Discov. 2024;5:164\u201379.","journal-title":"Blood Cancer Discov"},{"key":"1154_CR11","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood.2021014956","volume":"140","author":"AS Sperling","year":"2022","unstructured":"Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140:1753\u201363.","journal-title":"Blood"},{"key":"1154_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature. 2015;523:183\u20138.","journal-title":"Nature"},{"key":"1154_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/bloodadvances.2022007496","volume":"7","author":"EK Barnell","year":"2023","unstructured":"Barnell EK, Skidmore ZL, Newcomer KF, Chavez M, Campbell KM, Cotto KC, et al. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood Adv. 2023;7:236\u201345.","journal-title":"Blood Adv"},{"key":"1154_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2643-3230.BCD-22-0154","volume":"4","author":"R Kim","year":"2023","unstructured":"Kim R, Bergugnat H, Larcher L, Duchmann M, Passet M, Gachet S, et al. Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal Hematopoiesis. Blood Cancer Discov. 2023;4:134\u201349.","journal-title":"Blood Cancer Discov"},{"key":"1154_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219\u201326.","journal-title":"Nat Genet"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01154-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:03:48Z","timestamp":1728903828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01154-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01154-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. MICOL reports personal fees from Jazz Pharmaceuticals, from Astellas Pharma, from Servier, from AbbVie, from Gilead Sciences, from AstraZeneca, outside the submitted work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The systematic review of randomized controlled trials was performed in accordance to the PRISMA Harms Checklist guideline. No ethics committee approval or subject informed consent was obtained as this was a retrospective analysis of already published studies. The pharmacovigilance study in VigiBase\u00ae was approved by the Caen University Hospital Research Ethics Committee (#2646).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"177"}}